Evidence map›Paper›PMID 33446569›Full record

ArticleGenes & development2021

Protein-bound molybdenum cofactor is bioavailable and rescues molybdenum cofactor-deficient

Kurt Warnhoff, Thomas W Hercher, Ralf R Mendel, Gary Ruvkun

Open access · diamondAbstract read
In one paragraph

Article in Genes & development, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. XDH-1 inactivation causes xanthine stone formation inbioRxiv : the preprint server for biology · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Molybdenum Cofactor Deficiency in Humans.Molecules (Basel, Switzerland) · 2022
    Review
  11. The History of the Molybdenum Cofactor-A Personal View.Molecules (Basel, Switzerland) · 2022
    Review
  12. Review
  13. microPublication biology · 2022
    Article
  14. Review
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Kurt Warnhoff *Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts 02114.ORCID 0000-0002-9503-0557
Thomas W Hercher *Braunschweig University of Technology, 38106 Braunschweig, Germany.
Ralf R MendelBraunschweig University of Technology, 38106 Braunschweig, Germany.
Gary RuvkunDepartment of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts 02114.
Harvard University · USTechnische Universität Braunschweig · DE

Funding

CONTROL OF THE C ELEGANS LINEAGE BY HETEROCHRONIC GENESR01GM044619 · NIGMS · MASSACHUSETTS GENERAL HOSPITAL · PI GARY B RUVKUN · 1991 to 2026
$14.5M
NIGMS NIH HHS R01 GM044619
6 · The paper itself

Abstract

The molybdenum cofactor (Moco) is a 520-Da prosthetic group that is synthesized in all domains of life. In animals, four oxidases (among them sulfite oxidase) use Moco as a prosthetic group. Moco is essential in animals; humans with mutations in genes that encode Moco biosynthetic enzymes display lethal neurological and developmental defects. Moco supplementation seems a logical therapy; however, the instability of Moco has precluded biochemical and cell biological studies of Moco transport and bioavailability. The nematode

Indexed as

AnimalsBacteriaBiological TransportCaenorhabditis elegansCoenzymesHumansMetalloproteinsMetal Metabolism, Inborn ErrorsMolybdenum CofactorsProtein BindingPteridinesCoenzymesMetalloproteinsMolybdenum CofactorsmolybdopterinPteridinesC. elegansE. colimolybdenum cofactorsulfite oxidase

Identifiers

PMID33446569
PMCPMC7849362
OpenAlexW3123454008

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.